On 17 November 2026 the US Food and Drug Administration approved Lembaz (adrabetadex), made by Mandos, LLC, a subsidiary of Beren Therapeutics, to reduce the risk of death in people with infantile-onset Niemann-Pick disease type C (NPC). FDA says it is the first drug shown to help patients with the disease live longer, and the evidence is a survival comparison against matched external controls.
What happened
In a press announcement dated 17 November 2026, FDA said it approved Lembaz (adrabetadex) injection for adult and pediatric patients weighing at least 7 kg whose neurological manifestations of NPC began before age 6. The product is given intrathecally, meaning into the spinal canal, by a health care provider. The sponsor is Mandos, LLC, a subsidiary of Beren Therapeutics, PBC.
FDA described the disease as a rare inherited lysosomal storage disorder affecting about 1 in 150,000 people. It said two therapies had been approved for NPC before this action, but that neither has been shown to reduce the risk of death. Acting FDA Commissioner Kyle Diamantas was quoted in the announcement: “For the first time, there is a treatment shown to help adults and children with this serious disease live longer.”
Key details of the evidence
FDA stated that it examined the survival of 36 patients treated with Lembaz across three clinical studies and an expanded access program. All of them had neurological manifestations of NPC before age 6. Their outcomes were compared with a matched external control group and FDA reported that those patients had longer overall survival than the controls.
| Item | As stated by FDA on 17 November 2026 |
|---|---|
| Product | Lembaz (adrabetadex) injection |
| Sponsor | Mandos, LLC, a subsidiary of Beren Therapeutics, PBC |
| Population | Adults and children weighing at least 7 kg with neurological manifestations before age 6 |
| Evidence base | Survival of 36 treated patients in three clinical studies and an expanded access program, versus a matched external control group |
| Survival result | 55% reduction in the risk of death; median survival 8.5 years treated versus 4.9 years in controls |
| Concomitant miglustat | Benefit observed regardless of whether patients were also taking miglustat |
| Designation named by FDA | Breakthrough Therapy |
| Boxed warning | Hearing impairment, including permanent hearing loss |
FDA listed the common side effects as problems with hearing, balance and coordination, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea and cough. The label carries a boxed warning for hearing impairment, including permanent hearing loss, and FDA said a comprehensive hearing evaluation should be performed before starting Lembaz and regularly throughout treatment. Prescribing details are in the approved label, not in this report.
Background and context
The review ran longer than first scheduled. In a sponsor release carried by BioSpace on 23 February 2026, Beren said FDA had accepted the new drug application with priority review and a Prescription Drug User Fee Act (PDUFA) action date of 17 August 2026. The company described its evidence package as an externally controlled survival analysis intended to serve as a single adequate and well-controlled study, supported by biomarker data, nonclinical findings and patient experience data. It cited a hazard ratio of 0.289 against matched external controls, presented at the WORLD Symposium 2026, which it described as a 71% reduction in mortality risk. That is a sponsor-reported analysis; FDA’s own approval announcement gives the 55% figure above.
Contemporary Pediatrics reported on 28 May 2026 that the action date moved to 17 November 2026 after Beren’s 18 March 2026 response to an FDA information request, which FDA classified as a major amendment that extends the review clock by three months. The outlet called the extension a procedural update rather than a determination of efficacy, safety or approvability. It listed priority review, orphan drug designation and breakthrough therapy designation for the product, and noted that earlier clinical experience with intrathecal 2-hydroxypropyl-beta-cyclodextrin came from small, open-label studies and natural history comparisons, citing a 2017 Lancet phase 1-2 trial. Global Genes’ RARE Daily reported the same extension the same day and described average survival of just over five years in the most severe, early-onset cases.
Of the designations in that coverage, FDA’s approval announcement names only Breakthrough Therapy. For how the other expedited tools work, see the CASRAI entries on FDA priority review and the Prescription Drug User Fee Act.
Reaction
Beyond the FDA commissioner’s statement quoted above, the public record before the decision centred on patient urgency. In the May 2026 RARE Daily report, Beren chief executive Jason Camm emphasised the urgency for affected families, and the company said eligible patients could continue to receive adrabetadex through an expanded access program while the review was pending.
What it means for researchers, universities and research offices
The approval is a worked example of survival evidence assembled from an externally controlled comparison in an ultra-rare disease. Three practical points follow from what FDA and the sources above describe.
- Trial design: the 36-patient evidence base drew on three clinical studies and an expanded access program, so investigators planning rare-disease studies should note that outcomes gathered under expanded access formed part of what FDA examined. Protocols, data capture and consent language for such programs matter later, when the data are reused.
- Natural-history data: the matched external control group is only as good as the natural-history records behind it. Registries, longitudinal cohorts and curated disease datasets held by universities and patient organisations become regulatory-grade infrastructure, which puts weight on data quality, consistent outcome definitions and data-sharing agreements. The CASRAI guide to rare disease research covers study designs, registries and protocols.
- Divergent effect estimates: the sponsor reported a 71% reduction in mortality risk in its own analysis, while FDA stated 55%. Research offices supporting externally controlled analyses should expect matching methods, cohort selection and censoring to be scrutinised, and should keep the analysis plan and source data traceable.
The boxed warning also matters for study planning: hearing assessment is part of the monitoring FDA describes, so safety-monitoring plans for any future NPC trial that includes patients on this drug will need to account for it.
What happens next
The approval is effective as of FDA’s 17 November 2026 announcement, and the approved labeling, including the boxed warning and the hearing evaluation FDA says is needed before and during treatment, now governs use.
Sources
- FDA, press announcement on approval of Lembaz (adrabetadex) for infantile-onset Niemann-Pick disease type C, 17 November 2026
- Beren Therapeutics via BioSpace, FDA acceptance of the new drug application for adrabetadex, 23 February 2026
- Contemporary Pediatrics, FDA extends adrabetadex NDA review, 28 May 2026
- Global Genes RARE Daily, FDA extends review of Beren’s NPC therapy, 28 May 2026







